Improved results after heart-lung transplantation: a 17-year experience

Abstract

Changes in organ preservation management, surgical techniques, and immunosuppressive therapy significantly improved the short- and mid-term results after HLTx. Long-term results can only be improved in cases of successful prevention and treatment of OB.

Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part IV: Recipient-Related Risk Factors and Markers

“…27,75-78 Causes of early death or morbidity were usually separated into: (1) bleeding-related with need for transfusion or re-operation 22 ; and (2) respiratory failure, prolonged mechanical ventilation or donor organ failure. 29,79 Recent analyses have shown less difficulties with excessive hemorrhage. 27,79,80 Transfusion-related lung injury (TRALI) typically presents within 1 to 2 hours of the transfusion of a plasma-containing blood component.…”

“…29,79 Recent analyses have shown less difficulties with excessive hemorrhage. 27,79,80 Transfusion-related lung injury (TRALI) typically presents within 1 to 2 hours of the transfusion of a plasma-containing blood component. Patients with TRALI develop dyspnea, hypoxemia, hypotension and bilateral pulmonary edema, which is indistinguishable from acute respiratory distress syndrome (ARDS).…”

Dental management in transplant patients

“…Heart-lung transplant Combined heart-lung transplants are performed in cases of pulmonary hypertension with right side heart failure and Eisenmenger´s syndrome. The other indications are multi-organ end-stage disease, congenital abnormalities and amyloidosis, and simultaneous end-stage heart and lung disease (1,25).…”

Inconsistencies in the application of regulations about drug imports: A case report

“…In Europe, regulations about drug imports and exports were based on the fear of introducing unsafe drugs from countries where drug registration process may be light (Blanc 1997 Clinical context: Dextran 40 is a polymer with known inhibitory effects on complement system and intrinsic coagulation pathway; it is used as a graft-preservation solution in lung transplantation (Perfadex°) (Reichart et al 2003). As a drug (Rheomacrodex°), it was authorised as an intravascular fluid volume replacement solution and for prophylaxis of postoperative venous thrombosis.…”